Concord Biotech Ltd (CONCORDBIO) is listed on the NSE in the Pharmaceuticals sector, Pharmaceuticals & Biotechnology industry. Market capitalisation: 14858.64 Cr. Figures below are as reported and are shown with their source and date.
Concord Biotech Ltd is a IN-based company operating in Pharmaceuticals industry. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2023-08-18. Concord Biotech Limited is an India-based research and development driven biopharma company. The firm is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The firm manufactures active pharmaceutical ingredients (API) through fermentation and semi-synthetic processes and finished formulations. The company manufactures fermentation and semi-synthetic based products in the therapeutic segments, such as immunosuppressants, anti-bacterial, oncology, anti-fungal and others. Its API products include Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Vancomycin Hydrochloride, Micafungin Sodium, Mupirocin, Romidepsin, Dactinomycin, and Pravastatin Sodium, among others. The company also has a pipeline of API products under development. Its API products under development include Polymyxin B, Fidaxomicin, Doxorubicin, and others. The firm provides products in the critical care, immunology, nephrology, and transplant medicine segments.
Source: finedge · as of 2026-09-29
Last close (₹): 1,270
Source: quantro_screener_metrics_job · as of 2026-10-21
Source: quantro_screener_metrics_job · as of 2026-10-22
| Year ended | Revenue (₹ Cr) | PAT (₹ Cr) | EPS (₹) |
|---|---|---|---|
| Mar 2026 | 1,054.89 | 260.91 | 24.94 |
| Mar 2025 | 1,200.09 | 371.64 | 35.52 |
| Mar 2024 | 1,016.94 | 308.1 | 29.45 |
Source: finedge · as of 2026-07-21
Source: finedge · as of 2026-03-31
Source: quantro_company_profiles · as of 2026-10-23
Figures computed 2026-10-23.